Date: 2012-03-15
Type of information: Licensing agreement
Compound: AGE1.CR®avian cell line
Company: Ceva Santé Animale (France) ProBioGen (Germany)
Therapeutic area: Veterinary medicine
Type agreement: licensing
Action mechanism: AGE1.CR® is an immortalized cell line derived from primary cells of a Muscovy Duck. The cell line was created as a platform for replacing primary chicken cells for production of vaccines and hyper-attenuated viruses in chemically defined media and suspension cultures. In addition, AGE1.CR® cells are also suitable for the generation of trans-complementing helper or packaging cell lines to support efficient production of replication-restricted viral vectors. (See e.g. Biologicals. 2011 Jan;39(1):50-8 “A chemically defined production process for highly attenuated poxviruses”
Disease:
Details: Ceva Santé Animale and ProBioGen have announced the signature of a multi-product license agreement for the use of ProBioGen’s AGE1.CR®avian cell line in the industrial production of viral animal vaccines. In a preceding pilot study Ceva evaluated the technology, which allows cells to grow rapidly and in high cell densities in ProBioGen’s proprietary chemically defined medium. Master cell banking for one viral vaccine strain has been completed and further development projects are underway. An undisclosed number of animal vaccines are to be evaluated on the AGE1.CR® cell line. The commercial license includes milestone and royalty payments.
Financial terms: Financial details were not disclosed.
Latest news:
